<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

 <!--
<div class="home-btn nav-button loads-page">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
-->
<div class="goback-btn nav-button develop loads-page" data-pagelink="develop" style="display: absolute">
<!--<div class="goback-btn nav-button home-btn" style="display: absolute">-->
	<span>
		<img src="images/ashe-incyte-back-btn.png" alt="Back" title="Back">
	</span>
</div>
	<div class="container-fluid sd-main">
		<h2 class="text-center">Phase 2, International, Open-Label, Safety and Efficacy Study of INCB050465 (PI3K&delta; Inhibitor)<br> in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
		</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 study-rationale-nav modal-showx2" href="images/study-rationale/Incyte ASCO 2017 TS mockup INC-1195 citadel-202 (DLBCL).jpg">
				<h4 class="absolute-center"><img src="images/people-icon.png"><br>STUDY RATIONALE</h4>
			</div>
			<div class="col-xs-12 bg-blue primary-objectives-nav4">
				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav4">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav4">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top4" src="images/ashe-incyte-chevron.png">
			</div>

			<div class="sd-main-content4">
				<!-- section 1 -->
				<div class="scroll-wrapper" style="position: relative;">
					<div id="po4">
						<div class="absolute-cen">
						<h3>Primary objective:</h3>
						<ul>
						<li>Assess the efficacy of INCB050465 (PI3K&delta; inhibitor) (Group A)</li>
						</ul>
						<br>
						<h3>secondary objectives:</h3>
						<ul>
						<li>Assess the DOR, PFS, and OS (Group A)</li>
						<li>Characterize safety (Groups A and B)</li>
						</ul>
						</div>
					</div>
					<!-- section 2 -->
					<div id="sd4">
						<div class="absolute-cen">
						<h3>Study Design</h3>
						<img class="img-responsive" src="images/study-design/study-design2.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p> -->
						</div>
					</div>
					
					<!-- section 3 -->
					<div id="kiec4">
						<div class="absolute-cen">
						<h3 >Key inclusion criteria:</h3>
						<ul>
							<li>Age ≥18 years</li>
							<li>Histologically confirmed R/R diffuse large B-cell lymphoma, with ≥1 measurable nodal or extranodal lesion, and at least 1 but no more than 5 prior treatment regimens and ineligible for high-dose chemotherapy supported by autologous stem cell transplant </li>
							<li>Eastern Cooperative Oncology Group performance status 0 to 2</li>
						</ul>
						<br>
						<h3>Key exclusion criteria:</h3>
						<ul>
							<li>Primary mediastinal (thymic) large B-cell lymphoma</li>
							<li>Known brain or central nervous system metastases or history of uncontrolled seizures</li>
							<li>Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host-disease following allogeneic transplant, or autologous stem cell transplant within the last 3 months </li>
							<li>Prior treatment with the following: 
								<ul>
									<li><strong>Group A:</strong> Prior treatment with a selective PI3K&delta inhibitor (eg, idelalisib), a pan-PI3K inhibitor, or a BTK inhibitor (eg, ibrutinib)</li>
									<li><strong>Group B:</strong> Prior treatment with a selective PI3K&delta; inhibitor (eg, idelalisib) or a  pan-PI3K inhibitor</li>
								</ul>
							</li>
						</ul>
						</div>
					</div>
				</div>
			</div>

			<div class="liaison-box">
				<h6>To learn if any of your patients might be eligible for participation in these studies or to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>

			<div class="chevron-container btm">
				<img class="chevron-btm4" src="images/ashe-incyte-chevron.png">
			</div>
		</div>
	</div>

	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-offset-11 col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>
	</div>
	<!--<div class="develop-code">INC-1200e</div> -->
</div>


<div class="pop-up-div studydesign">
	<p>BTK = Bruton's tyrosine kinase, DOR = duration of response, OS = overall survival, PFS = progression-free survival, PI3K&delta; = phosphatidylinositol-3 kinase delta, R/R = relapsed or refractory</p>
</div>